Remove 2023 Remove Communication Remove Generic Medicine
article thumbnail

Navigating tariffs and diplomacy: the future of India-US pharmaceutical trade

Pharmaceutical Technology

Go deeper with GlobalData Reports Future of Pharma - Looking Ahead to 2023 Reports China Contract Manufacturing Market Outlook - Trends, Ambitions, Ke. If successful, India will become the first country to sign a bilateral trade agreement (BTA) of such with the US during President Trump’s second term in the White House.

article thumbnail

What a mild recession could mean for small biotechs in 2023

Pharmaceutical Technology

in 2022 to 1% in 2023 due to the “tightening of monetary and financial conditions”. Furthermore, for months, several financial institutions such as Bank of America and JP Morgan have been talking of a “mild recession” in 2023 for the US. by the end of 2023 and may continue to rise in 2024 to 5%.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Medicine and medical device shortages: what’s been done and what’s to do

Hospital Pharmacy Europe

In 2022, the Executive Steering Group on Shortages and Safety of Medicinal Products was established to ensure a robust response to medicine supply issues caused by major events or public health emergencies. All of the results highlighted the far-reaching consequences of medicines shortages in daily practice.

article thumbnail

Cyclobenzaprine interactions to avoid

The Checkup by Singlecare

It’s usually dispensed in pharmacies as a generic medicine, but healthcare providers commonly refer to it by brand names Flexeril (immediate-release tablets), Fexmid (immediate-release tablets), or Amrix (extended-release capsules). Cyclobenzaprine is a prescription muscle relaxant that is approved by the U.S. as a brand-name drug.